Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals (SNOA) showed zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, indicating no acute distress signals in the recent period. However, low signal in a short window doesn't eliminate structural risks—the company operates in a capital-intensive sector where dilution, financing patterns, and cash runway merit deeper analysis. Our full $49 Report extends the lookback to 12 months, calculates dilution risk scores, maps the complete 8-K and financing history, and flags AI-detected anomalies in SEC language that short-window scans miss. The full $49 Report adds quantified dilution trajectory, financing dependency analysis, and 12-month red-flag context.